Best Practices in COPD
Practical Updates on the 2023 GOLD Guidelines
Once-daily single-inhaler triple versus dual therapy in patients with COPD.
Lipson DA, et al. N Engl J Med. 2018; 378(18):1671-1680.
The effect of exacerbation history on outcomes in the IMPACT trial.
Halpin DMG, et al. Eur Respir J. 2020;55(5):1901921.
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
Lipson DA, et al. Am J Respir Crit Care Med. 2020; 201:1508–1516.
Disease severity and symptoms among patients receiving monotherapy for COPD
Dransfield MT, et al. Prim Care Respir J. 2011;20(1):46-53.
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
Maltais F, et al. Respir Res. 2019;20(1):238.
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal
Celli BR, et al. Am J Respir Crit Care Med. 2021;204(11):1251-1258.
Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD.
Rabe KF, et al. N Engl J Med. 2020;383(1):35-48.
Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study.
Martinez FJ, et al. Am J Respir Crit Care Med. 2021;203(5):553-564.
PRIMUS - Prompt Initiation of Maintenance Therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation.
Tkacz J, Evans KA, Touchette DR, et al. Int J Chron Obstruct Pulmon Dis. 2022;17:329-342.
INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice.
Halpin DMG, Worsley S, Ismaila AS, et al. ERJ Open Res. 2021;7(2):00950-02020.
Guidelines
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2023 report.
Clinical management of COVID-19: living guidance.
World Health Organization. September 2022.
Clinical Practice Tools and Resources
The COPD Foundation Pocket Consultant Guide Mobile App
The COPD Pocket Guide, provided by the COPD Foundation, contains comprehensive management information as well as resource tools. It can be downloaded onto any mobile device.
Modified Medical Research Council (mMRC) Dyspnea Scale
The mMRC scale, provided by MDCalc, allows for the baseline stratification of dyspnea in COPD, as well as other respiratory diseases.
COPD Control Questionnaire (CCQ)
The CCQ measures health status and can be used to assess health-related quality of life (HRQL).
COPD Assessment Test (CAT)
The CAT, provided by the American Academy of Family Physicians, allows assessment of the global impact of COPD (cough, sputum, dyspnea, chest tightness) on patient health status.
COPD Action Plan
The COPD Action Plan, provided by the American Lung Association, is a tool that facilitates the prevention, timely identification, and early and appropriate treatment of COPD exacerbations.
ATS Telemedicine Information Series
The American Thoracic Society offers patients educational materials on telemedicine as well as answers to frequently asked questions surrounding this topic.
Patient Resources and Advocacy Organizations
The COPD Foundation Pocket Consultant Guide Patient-Focused Mobile App
The COPD Pocket Guide for Patients was designed to improve disease management and communication with a patient’s health care team. It includes patient resources such as inhaler and exercise videos as well as tools such as the wallet card and daily symptom tracker that help collect and share information with the health care team. It can be downloaded onto any mobile device.
American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.
COPD Foundation
The COPD Foundation’s mission is to prevent and cure COPD and to improve the lives of all people affected by COPD.
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
GOLD partners with health care professionals and public health officials to raise awareness of COPD and to improve prevention and treatment of this lung disease for patients around the world.
National Jewish Health
National Jewish Health integrates the latest scientific discoveries with coordinated care for lung, heart, and immune diseases. Their Patient Education Program provides many free educational opportunities and support groups to assist patients and caregivers with managing illnesses and chronic conditions, such as COPD.
Overview of the 2023 GOLD Guidelines for COPD
Module 1
| Faculty: | Fernando J. Martinez, MD |
| Release: | 12/15/2022 |
| Expiration: | 12/15/2023 |
2023 GOLD COPD Guideline Updates to Patient Assessment
Module 2
| Faculty: | Fernando J. Martinez, MD; Charles P. Vega, MD, FAAFP |
| Release: | 01/17/2023 |
| Expiration: | 01/17/2024 |
2023 GOLD COPD Guideline Updates to Therapeutic Strategies
Module 3
| Faculty: | Fernando J. Martinez, MD; Charles P. Vega, MD, FAAFP |
| Release: | 01/17/2023 |
| Expiration: | 01/17/2024 |
2023 GOLD COPD Guideline Updates on Comprehensive Patient Management
Module 4
| Faculty: | Fernando J. Martinez, MD; Charles P. Vega, MD, FAAFP |
| Release: | 01/17/2023 |
| Expiration: | 01/17/2024 |
